Table 1.
Baseline characteristics by cohort among people living with HIV engaged in HIV care.
| Overall |
Genotyped |
PRO cohort |
||||
|---|---|---|---|---|---|---|
| Female | Male | Female | Male | Female | Male | |
| N=6,105 | N=27,893 | N=1,445 | N=6,017 | N=2,844 | N=12,827 | |
| Demographics | ||||||
| Age at study entry, median (IQR) | 39 (31-46) | 39 (31-46) | 39 (32-46) | 40 (33-46) | 39 (32-47) | 39 (31-47) |
| Hispanic, n (%) | 479 (7·9) | 3,629 (13·0) | 67 (4 6) | 603 (10 0) | 252 (8 9) | 1,895 (14 8) |
| Black race, n (%) | 3,909 (64 0) | 9,301 (33·4) | 1,006 (69 6) | 2,248 (37 4) | ||
| HIV Characteristics | ||||||
| ARV at baseline, n (%) | 3,152 (50·8) | 14,966 (52·4) | 794 (55·0) | 3,016 (50 1) | 1,391 (48 9) | 5,907 (46 1) |
| CD4 count, median (IQR) | 363 (168-588) | 351 (158-557) | 352 (154-572) | 319 (129-521) | 381 (179-608) | 362 (172-566) |
| Log viral copy-years, median (IQR) | 9·8 (7·8-11 3) | 9 4 (7 5-11 0) | 10 6 (9 0-11 8) | 10 2 (8 4-11 5) | 9 8 (7 8-11 4) | 9 3 (7 4-11 1) |
| Comorbid Conditions | ||||||
| HCV infection, n (%) | 1,574 (25·8) | 5,313 (19.1) | 397 (27 5) | 1,365 (22 7) | 655 (23 0) | 2,344 (18 3) |
| HBV infection, n (%) | 222 (3·6) | 1,781 (6·4) | 66 (4 6) | 471 (7 8) | 100 (3 5) | 809 (6 3) |
| Diabetes, n (%) | 1,007 (16·6) | 2,930 (10·6) | 343 (23 8) | 1,076 (17 9) | 619 (21 9) | 1,803 (14 1) |
| Hypertension, n (%) | 1,023 (16·9) | 2,781 (10.1) | 601 (21 2) | 1,529 (12 0) | ||
| 2 APOL1 risk variantsa, n (%) | – | 148 (10·2) | 350 (5·8) | |||
| ≥50% African ancestry | – | 1,003 (69 4) | 2,224 (37 0) | |||
| Baseline creatinine, median (IQR) | 0·8 (0·7-1·0) | 1·0 (0·9-1·2) | 0 9 (0·7-1·1) | 1 1 (0 9-1 2) | 0 9 (0 7-1 0) | 1 0 (0 9-1 2) |
| Baseline eGFR, median (IQR) | 93 (71-112) | 94 (77-109) | 85 (63-103) | 87 (70-103) | 88 (69-106) | 89 (74-104) |
| BMI, kg/m2 | ||||||
| <19 | 333 (6 0) | 1,025 (4 0) | 62 (4 5) | 221 (3 8) | 136 (4 8) | 470 (3 7) |
| 19-24 | 1,894 (34 2) | 12,141 (47 8) | 456 (33 1) | 2,724 (46 4) | 891 (31 7) | 5,928 (46 8) |
| 25-29 | 1,506 (27 2) | 8,778 (34 6) | 405 (29 4) | 2,108 (35 9) | 789 (28 0) | 4,429 (35 0) |
| ≥30 | 1,801 (32 5) | 3,456 (13 6) | 453 (32 9) | 820 (14 0) | 999 (35 5) | 1,841 (14 5) |
| Patient Reported Outcomes | ||||||
| High risk alcohol abuse | – | – | 397 (14 0) | 2,183 (17 0) | ||
| IDU | – | – | 189 (14.2) | 1,213 (18 8) | ||
| Methamphetamine use | – | – | 395 (14 6) | 4,660 (37 3) | ||
| Marijuana use | – | – | 1,327 (48 9) | 8,602 (69 0) | ||
| Illicit opioid use | – | – | 473 (18 3) | 2,418 (19 9) | ||
| Cocaine/crack use | 985 (36 2) | 5,928 (4761) | ||||
| Study Entry Era | ||||||
| 1995-1999 | 1,088 (17 8) | 4,062 (14 6) | 352 (24 4) | 1,188 (19 7) | 335 (11 8) | 1,134 (8 8) |
| 2000-2004 | 1,696 (27.8) | 6,791 (24 4) | 484 (33 5) | 1,584 (26 3) | 594 (20 9) | 2,159 (16 8) |
| 2005-2009 | 1,346 (22 1) | 6,834 (24 5) | 423 (29 3) | 2,063 (34 3) | 742 (26 1) | 3,414 (26 6) |
| 2010-2014 | 1,371 (22 5) | 6,993 (25 1) | 184 (12 7) | 1,153 (19 2) | 883 (31 1) | 4,381 (34 2) |
| 2015-2020 | 604 (9.9) | 3,213 (11 5) | 2 (0 1) | 29 (0 5) | 290 (10 2) | 1,739 (13 6) |
a
Among genotyped only.
ARV: antiretroviral use, HCV: hepatitis C virus, HBV: hepatitis B virus, APOL1: apolipoprotein 1, eGFR: estimated glomerular filtration rate, CKD: chronic kidney disease, IDU: intravenous drug use.